ClinicalTrials.gg
Status unknownNCT06116383Updated Nov 7, 2023

Evaluation of Renal Perfusion With NIRS in Laparoscopic Surgery

An observational study in Pneumoperitoneum and Renal Injury, sponsored by Diskapi Yildirim Beyazit Education and Research Hospital. Status unknown at 1 site in Turkey (Türkiye). Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2023-11-07.

Sponsored by Diskapi Yildirim Beyazit Education and Research Hospital · Observational

The sponsor has not verified this record recently (last verified Nov 2023), so the status shown — last known as Not yet recruiting — may be out of date.
Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
58
Ages
18 Years to 85 Years
Sex
All
01

Study summary

The investigators aimed to show the renal damage caused by increased intra-abdominal pressure in laparoscopic surgeries and to investigate whether its reflection on NIRS would be clinically effective.The main question it aims to answer are:

Does pneumoperitoneum cause renal damage?

NRS monitoring will be performed in patients undergoing laparoscopic surgery. Preoperative and postoperative blood tests will be performed at certain hours. N-GAL, urea and creatinine values will be recorded.

Read the detailed description

Renal NIRS monitoring will be performed in patients undergoing laparoscopic cholecystectomy surgery. Age, gender, BMI, ASA scores, hemogblin/hematocrit values, intraoperative hemodynamic parameters, NIRS values, N-GAL (preoperative, 2nd hour and 24th hour), urea/creatinine (preoperative, postoperative 24th hour) values of the patients will be recorded. .

Before the general anesthesia is performed, the renal tissues of the patients will be visualized by ultrasound, the skin-renal cortex distances will be measured, and suitable patients will be included in the study. Basal rSO2 values will be recorded by placing NIRS probes under the 10-11. intercostal space in the bilateral posterior lateral flank region.

02

Conditions studied

  • Pneumoperitoneum
  • Renal Injury

Browse trials for

Keywords

  • laparoscopy
  • NIRS
  • N-GAL
03

In context

Pneumoperitoneum

134 studies on the registry are indexed under Pneumoperitoneum; 28 are open to participants now.

This study's planned enrollment of 58 is close to the median of 59 across 48 observational studies indexed under Pneumoperitoneum.

Browse Pneumoperitoneum studies →

Lead sponsor

Diskapi Yildirim Beyazit Education and Research Hospital is the lead sponsor of 71 studies on the registry; 12 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Patients who undergoing elective laparoscopic cholecystectomi surgery

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients who undergoing elective laparoscopic cholecystectomi surgery lasting longer than 60 minutes
  • :18-25
  • skin-renal cortex distance measured less than 4 cm on ultrasound

Exclusion criteria

Exclusion Criteria:

  • patient who did not give consent
  • patient who had renal operation before,
  • infection, abscess, catheter in the perirenal region
  • hemodynamically unstable patients,
  • patients with renal pathology and abnormal kidney function tests,
  • emergency cases
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

05

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
58 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Patients undergoing laparoscopic cholecystectomy.

    Basal rSO2 values will be recorded by placing NIRS probes under the 10-11th intercostal space in the bilateral posterior lateral flank region. Age, gender, BMI, ASA scores, Hb/Htc values, intraoperative hemodynamic parameters, NIRS values, N-GAL (preoperative, 2nd hour and 24th hour), urea/creatinine (preoperative, postoperative 24th hour) values of the patients will be recorded. .

    Device: NIRS

Interventions

  • DeviceNIRS

    Renal perfusion will be evaluated with NIRS

06

What researchers measure

Primary outcomes

  1. Evaluation of renal damage caused by pneumoperitoneum with N-GAL by blood test

    Taking a blood test to evaluation N-GAL

    Time frame: During laparoscopic cholecystectomy operation and within 24 hours postoperative

  2. Evaluation of renal damage caused by pneumoperitoneum with urea/creatinin by blood test

    Taking a blood test to evaluation urea/creatinine values

    Time frame: During laparoscopic cholecystectomy operation and within 24 hours postoperative

07

Study locations

1 site
  • Department of Anesthesiology and Reanimation, University of Health Sciences, Diskapi Yıldırım Beyazit Training and Research Hospital
    Ankara, 06450, Turkey (Türkiye)
08

References and documents

Publications

  • Caliskan E, Sanal Bas S, Onay M, Kilic Y, Kayhan Erdogan G, Tokar B. Evaluation of renal oxygenization in laparoscopic pediatric surgery by near infrared spectroscopy. Pediatr Surg Int. 2020 Sep;36(9):1077-1086. doi: 10.1007/s00383-020-04709-w. Epub 2020 Jul 10. PubMed 32651617 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2023; primary completion for Apr 2024, 4 months later.

Of 26 observational studies under Pneumoperitoneum, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 17. This study's planned 4 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 28, 2023
First posted
Nov 3, 2023
StartEst.
Nov 10, 2023
Primary completionEst.
Apr 1, 2024
CompletionEst.
May 1, 2024
Last update
Nov 7, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 7, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06116383
Lead sponsor
Diskapi Yildirim Beyazit Education and Research Hospital
Responsible party
Savas Altinsoy (Associate Professor MD, Diskapi Yildirim Beyazit Education and Research Hospital) — Principal investigator
First posted
Nov 3, 2023
Start date
Nov 10, 2023 (estimated)
Primary completion
Apr 1, 2024 (estimated)
Completion
May 1, 2024 (estimated)
Last update
Nov 7, 2023

Study contacts

Savaş Altınsoy, MD
Contact
savasaltinsoy@gmail.com
0905332257104
Savaş Altınsoy, MD
study chair · Ankara Etlik City Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion